NUGALVIQ
Live / Applied — First extension granted (statement of use) (as of 11 Nov 2025)
What this means for you
Not registered yet, but its 07 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98787898
- Mark type
- Stylized text
- Filed
- 07 Oct 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Anna Kurian Shaw
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG)
Owner
- Applied Therapeutics, Inc., New York, NY, US
- Applied Therapeutics, Inc., New York, NY, US
Prosecution history
- 12 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Nov 2025 — SOU EXTENSION 1 GRANTED
- 11 Nov 2025 — SOU EXTENSION 1 FILED
- 11 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Apr 2025 — PUBLISHED FOR OPPOSITION
- 09 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Mar 2025 — ASSIGNED TO EXAMINER
- 07 Oct 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 07 Oct 2024 — NEW APPLICATION ENTERED